Literature DB >> 23168297

A mouse mammary epithelial cell line permissive for highly efficient human adenovirus growth.

Chengjun Wu1, Daniel Öberg, Asif Rashid, Rajesh Gupta, Marco Mignardi, Staffan Johansson, Göran Akusjärvi, Catharina Svensson.   

Abstract

Although a few immunocompetent animal models to study the immune response against human adenoviruses (HAdV) are available, such as Syrian hamsters and cotton rats, HAdV replication is several logs lower compared to human control cells. We have identified a non-transformed mouse epithelial cell line (NMuMG) where HAdV-2 gene expression and progeny formation was as efficient as in the highly permissive human A549 cells. HAdV from species, D and E (HAdV-37 and HAdV-4, respectively) also caused a rapid cytopathic effect in NMuMG cells, while HAdV from species A, B1, B2 and F (HAdV-12, HAdV-3, HAdV-11 and HAdV-41, respectively) failed to do so. NMuMG cells might therefore be useful in virotherapy research and the analysis of antiviral defense mechanisms and the determination of toxicity, biodistribution and specific antitumour activity of oncolytic HAdV vectors.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 23168297     DOI: 10.1016/j.virol.2012.10.034

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  2 in total

Review 1.  Non-Human Primate-Derived Adenoviruses for Future Use as Oncolytic Agents?

Authors:  Selas T F Bots; Rob C Hoeben
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

2.  Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.

Authors:  Janet Lei; Egon J Jacobus; William K Taverner; Kerry D Fisher; Silvio Hemmi; Katy West; Lorna Slater; Fred Lilley; Alice Brown; Brian Champion; Margaret R Duffy; Len W Seymour
Journal:  J Immunother Cancer       Date:  2018-06-13       Impact factor: 13.751

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.